Cerebrospinal fluid levels of soluble amyloid precursor protein and ß-amyloid 42 in patients with multiple sclerosis, neuromyelitis optica and clinically isolated syndrome.
AuthorsMai W, Hu X, Lu Z, Peng F, Wang Y,
JournalJ Int Med Res
PubMed ID22289560
'Amyloid precursor protein (APP) accumulation in axonal ovoids is a sensitive marker for acute axonal injury in multiple sclerosis (MS) lesions. This study measured levels of a-cleaved soluble APP (a sAPP) and ß-amyloid 42 (Aß42) in the cerebrospinal fluid (CSF) of 42 MS, 10 neuromyelitis optica and 25 clinically isolated ... More
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
AuthorsLi G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ
JournalNeurology
PubMed ID17698783
'BACKGROUND: Processes of Alzheimer disease (AD) likely begin years prior to the onset of cognitive impairment (latent AD), progress though a prodromal phase of mild cognitive impairment (MCI), and culminate in dementia. While many studies have evaluated CSF tau and Abeta(42) as biomarkers of the dementia or prodromal stages of ... More
Biochemical markers in persons with preclinical familial Alzheimer disease.
AuthorsRingman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL
JournalNeurology
PubMed ID18509095
Persons at risk for familial Alzheimer disease (FAD) provide a model in which biomarkers can be studied in presymptomatic disease.
Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer's disease by color-coded bead technology.
AuthorsChoi C, Jeong JH, Jang JS, Choi K, Lee J, Kwon J, Choi KG, Lee JS, Kang SW
JournalJ Clin Neurol
PubMed ID19513308
The availability and promise of effective treatments for neurodegenerative disorders are increasing the importance of early diagnosis. Having molecular and biochemical markers of Alzheimer's disease (AD) would complement clinical approaches, and further the goals of early and accurate diagnosis. Combining multiple biomarkers in evaluations significantly increases the sensitivity and specificity ... More
[F-18]FDDNP microPET imaging correlates with brain Aß burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aß antibody treatment.
AuthorsTeng E, Kepe V, Frautschy SA, Liu J, Satyamurthy N, Yang F, Chen PP, Cole GB, Jones MR, Huang SC, Flood DG, Trusko SP, Small GW, Cole GM, Barrio JR,
JournalNeurobiol Dis
PubMed ID21605674
In vivo detection of Alzheimer's disease (AD) neuropathology in living patients using positron emission tomography (PET) in conjunction with high affinity molecular imaging probes for ß-amyloid (Aß) and tau has the potential to assist with early diagnosis, evaluation of disease progression, and assessment of therapeutic interventions. Animal models of AD ... More